Search

Displaying results 2851 - 2860 of 6076 in total
  1. Drug

    Lomifylline

    go.drugbank.com/drugs/DB18002
    Approved

    Categories: Drugs for Obstructive Airway Diseases
  2. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols.

  3. Drug

    Practolol

    go.drugbank.com/drugs/DB01297
    Approved

    A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.

  4. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages.

  5. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Deficiency of C1-inhibitor allows for increased plasma kallikrein activation and subsequent production of bradykinin. … Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.

  6. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive.

    Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain
  7. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate can...

  8. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Initial trials of ligelizumab suggest a greater efficacy over its predecessor for the treatment of CSU.[A242367] … [A242292] Ligelizumab is currently under investigation for the treatment of chronic spontaneous urticaria (CSU), an autoimmune-driven inflammatory condition.

  10. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]